Immunohistochemical analysis has indicated high levels of SLC3A2 expression in tumor tissues, and the highest levels of SLC3A2 expression have been observed in high-grade gliomas (Fig. 2H). This evidence concerns the gene SLC3A2 and central nervous system cancer.